Administration of thrombolytic therapy in the community hospital: Established principles and unresolved issues  by Mark, Daniel B. et al.
32A JAW Vol. 12. No 6 December I Y R R  32A43A 
PRACTICAL ASPECTS 
Administration of Thrombolytic Therapy in the Community Hospital: 
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In patients with acute myocardial infarction presenting to 
community hospitals, thrombolytic therapy should be ini- 
tiated as rapidly as possible under the supervision of a 
physician. Paramedic or  nurse-initiated pre-hospital ther- 
apy is currently investigational. Each hospitat must have a 
detailed evaluation and treatment protocol for acute myo- 
cardial infarction that specifies the timetable for patient 
evaluation, who should or  should not receive thrombolytic 
therapy and the proper dose and mode of administration of 
the agent or  agents to be used. 
Monilorhrg after the administration of thrombotytic 
Large randomized controlled trials (l-4) have now conclu- 
sively shown that thrombolytic therapy improves survival in 
acute myocardial infarction. This effect is believed to be 
primarily due to the reestablishment of infarct vessel pa- 
tency, thereby promoting myocardial salvage and, presum- 
ably, improved myocardial healing (5-10). Experimental 
studies (5.7.1 I) have established that myocardial salvage has 
an important temporal relation with the duration of coronary 
occlusior,. and both experimental and clinical data support 
the concept that myocardial salvage is minimal when coro- 
nary blood Row has been interrupted for more than 4 to 6 h. 
Therefore. the recent findings of the Second International 
Study of Infarct Survival (ISIS-2) (3) that streptokinase 
improves survival when given up to 24 h after the onset of 
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therapy should focus on arrhythmias, hemodynamic proh-  
lems, recurrent ischemia and b!eedtng. The ro!e of early 
cardiac catheterization to detect patients who have unsuc- 
cessful thrombolysis or  who require mechanical revascular- 
tration procedures is under active investigation. The design 
of the Thrombolysis and Angioplasty in Acute Myocardiat 
lnfaretion (TAMI) 5 study, whieh addresses the rote of 
acute interventional catheterization in the treatment of 
patients with acute myocardial infarction, ls described. 
(.I Am Coil Cardiol1988;12:32A-43A) 
symptoms of infarction challenge the notion that myocardial 
salvage is a prerequisite for improved survival. Both ISIS-2 
and the Gruppo Italian0 per lo Studio della Streptochinasi 
nell’lnfarto Miocardico (GISSI) trial, however, found that 
patients treated very early (within the time window for 
myocardial salvage) had a larger reduction in mortality that 
did those treated later; the in-hospital mortality rate was 
reduced by a dramatic 47% in GISSI patients (I) and by 45% 
in ISIS-2 patients (3) receiving streptokinase within the 1st h 
of symptom onset. These studies have firmly established 
thrombolytic therapy as a central part of the standard care 
for patients in the early phase of an acute myocardial 
infarction. 
Limitations of therapy. Despite the established benefits 
of thrombolysis, this form of therapy has several notable 
limitations. First, t; : time dependency of survival benefits 
with thrombolys;s mandates that patients receive medical 
attention promptly after the onset of symptoms to maximize 
the benefits of therapy. Unfortunately, only about half of 
patients eligible for therapy present to an emergency room 
within 12 h of :ymptom onset, and a substantial minority 
may delay seeking medical attention for several days 
(I ,12.13). Second, currently available intravenous throm- 
bolytic agents achieve rapid reperfusion in only 50 to 75% of 
patients t&14-17). Thus, at least one in every four treated 
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Table 1. Thrombolyfic Therapy: LimltatlonT and 
Potential Solutions 
-  -~ 
I .  Patient delay m prcwtmg IO  medical dttentmn 
Mas public education about symptom\ of myocxdul m&rctmn 
Prc-hosp&d adm#nWntlon of thrombolvuc ther.Bpy 
2. Reperfuyion ceiling of currently dvdddble dgenl\ 
Emergency cathe~enzauon and “re~e” coronq mgtopls~ly 
More effective thrombolyuc regm~en~ 
3. Residual subtotal (tenor an Infarct-relat*.d ~tery after !hmmboly\l~ 
Early catheterization and reva~lanrat~on 
Medical regimens to prevent ~~OCL~UIIO~ 
tom\ ,md mlti+nn of therapy is very small. practitioners 
must be prepared to decide about the use of thrombolytic 
therapy m pattents with a potential acute myocardial infarc- 
tlon wlthm IS min of ho\p;ial arrival (21). Such efficiency 
rcqulre\ a written protocol and a well rehearsed and co< di- 
nated effort among physicians. emergency room nurse\ and 
emergency medical transport personnel. 
Patient delay in weking treatment. Even with the most 
efficient emergency room protocol, however. many patients 
wdl not recC,vc early treatment because of their own delay in 
\eeking medical attenlion. Previous studies (22)  have dem- 
on\trated that approximately 50% of the delay in reaching 
the hospital is due to patient indecision. Interestingly. pa-  
tients with known heart disease or  major cardiac risk factors 
have the longest delay times (13.23). Efforts by organizations 
quch a~ the American iieart Associalion to educate ihe 
public at large about the early symptoms of a heart attack 
may reduce this patient delay somewhat. particularly with 
pubhcity about the much improved prognosis associated 
with early diagnosis and treatment. 
Pre-hospital thrombolytic therapy. Another IO tr IS% of 
:he delay tn the arrival of patients IO an emergency room is 
accounted for by transport time (22). This delay could be 
shortened significantly by pre-hospital administration of 
thrombolytic therapy. Furthermore. because emergency 
med!cdl techmcians usually spend time evaluating patients 
before providing transport, using that evaluation as the ba++ 
for the deciston to treat would eliminate the need for a repeat 
pretreatment evaluation in the emergency room. 
Several small studies have investigated the use of throm- 
boly!ic !henpy “in the field.” In one study (24). physicians 
riding with a mobile coronary care unit made a dtagnosls oi 
acute myocardial infarction in nine patients using clinical 
and electrocardiographic (ECG) data and initiated intrave- 
nous streptokinase therapy at the patient’s home. These 
patients had an average time to treatment that was 45 min 
shorter than that of 44 other patients treated with the same 
protocol after arrival in the emergency room. The overall 
coronary patency rate in the study assessed at 4 IO 9 days 
after therapy was 81%. The pre-hospital treatment group had 
a smaller infarct iasscssed hy peak creatine kinase [CKI 
values and by QRS scores) and had signiiicaz!!), improved 
left ventricular function compared with the hospital treat- 
ment group (ejection fraction 67% for the pre-hospital grou; 
versus 48% for the hospital group). Another preliminary 
report (25)  investigating pre-hospital thrombolytic theraT! 
noted tha: physicians in the field correctly excluded patients 
with pericarditis and aortic dissection from treatment. These 
investigators observed no serious pre-hospital complications 
after administering thrombolytic therapy to 75 patients in the 
home. 
Two nwjor concerns /we been rcriwd about pre-kospild 
~~~,rir~isrrcrrk,,~ of rkromhulyric rherrrpy (22). First. it is 
uncertain whether paramedical personnel can make an ac- 
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curate clinical diagnosis of acute myocardial infarction with 
appropriate evaluation for conditions in which therapy 
would be contraindicated (such as aortic dissection or  acute 
pericarditis). Weaver and Cobb (22)  have initiated a I year 
pilot project in Seattle, Washington IO evaluate this issue 
directly. In their study, paramedics are evaluating patients in 
the field using a defined protocol that includes remote 
transmission of a I2 lead ECG lo a hospital-based physician 
for interpretation. During this pilot phase, the decision lo 
treat or  not io treat is recorded, but no treatment is actually 
given in the field. If this trial shows that diagnosis can be 
made accurately in the field, a second phase will be initiated 
involving randomization of patients lo pre-hospital versus 
hospital administration of recombinant tissue plasminogen 
activator (rt-PA). 
A secottd mrwnt with pre-lmpircd thrmh,!vtic therapy 
relates IO whether earlier treatment will be associated with 
an unacceptable risk of reperfusion arrhythmias (22.26). 
Currently available data (1.7.27-29) suggest that the risk of 
serious arrhythmias in patients who have successful reper-  
fusion is not significantly higher than that in patients who 
have unsuccesstul lhromboiyiic therapy or  who do not 
receive it. Arrhythmias, when they do occur. can be man- 
aged effectively in the field by well trained paramedical 
personnel. One potential problem has been suggested by 
experimental studies (26)  in which very malignant and re-  
fractory ventricular arrhythmias were observed in animals 
subjected IO only a short period of coronary occlusion 
followed by reperfusion. Chnically. however, there has been 
no evidence for a malignant ventricular arrhythmia associ- 
ated with very early reperfdsion and, in fact, the best 
survival rales in th: GiSSl (I.?) and ISIS-2 (3)  trials were 
seen in those patients treated within I h  of symptom onset. 
A rcrdiccd crpprmch to curly thrornbolytic tkercrpy in- 
vo/vc.~ potieut self-crdf,lirristrrrrio,l. The use of intramuscular 
rt-PA was tested in an animal model by Sobel et al. (30). 
Potential problems of intramuscular fibrinolytic therapy in- 
clude reduced absorption. reduced plasma levels and intra- 
muscular hematoma formation. Furthermore, the problems 
involved in ensuring accurate self-d!agnosis and adequate 
monitoring once lherapy is given must be adequately re-  
solved before this approach can be recommended. 
in the early phase of the thrombolytic era, concern about 
the harm that could be caused by inappropriate administra- 
tion of streptokinase led many communities lo establish 
protocols that limited the use of this agent IO cardiologists 
(31). Communitie\ without cardiologists often did not use the 
drug at all. Enough experience has now been gained, how- 
ever, lo show that thrombolytic therapy can be safely 
initiated by any physician who has had adequate training 
about the risks and benefits. provided that there is an 
appropriate treatment protocol IO follow and a treatment 
environment in which the nursing staff is also properly 
educated. Patient enrollment in the GISSI study and the 
ISIS-2 trial was performed predominantly by emergency 
room physicians in community hospitals. 
Treatment efficacy. Several studies (32-34)  have now 
documented the efficacy of thrombolytic !hcrapy in commu- 
nity hospitals in the United States. McNamara et al. (34)  
reported similar reperfusion and complication rates after 
administration of streptokinase in a tertiary care hospital and 
in several rural community hospitals. In our  series (35)  of 342 
consecutive patients treated with intravenous streptokinase 
and referred for immediate angiography, approximately 50% 
had treatment initiated at a small community hospital with- 
out a cardiologist available. Top01 et al. (36)  found that 
patients who were treated with r&PA in 9 community hos- 
pital before they were taken to an interventional facility 
tended to have higher reperfusion rates and better left 
ventricular function than did similar patients who were taken 
to the facility before initiation of therapy. 
Monitoring After Therapy 
Once the decision is made to administer thrombolytic 
therapy, the medical system must be prepared IO provide 
careful monitoring of the patient so that complications can 
be recognized and treated promptly and the benefits of 
therapy can be maximized. Monitoring should focus on four 
clinical areas: arrhythmias, hemodynamic difficulties, recur- 
rent ischemia and bleeding complications (21). With a com- 
prehensive protocol and proper in-service education, ade-  
quate monitoring after thrombolytic therapy can be 
accomplished in any size hospital. 
ST elevation and chest pain. Early reports of intracoro- 
nary thrombolytic therapy described an association between 
coronary reperfusion and resolution of ST segment elevation 
and chest pain. It was therefore hoped that monitoring of ST 
segments and chest pain status could provide a reliable guide 
to the efficacy of therapy. Unfortunately, several studies 
(28.29.37) have now demonstrated that, although the relation 
between reperfusion and resolution of ST segment elevation 
and chest pain is statistically significant, it is not precise 
enough lo allow the clinician to predict reperfusion accu- 
rately. In pan, this is because the natural course of acute 
myocardial infarction without reperfusion includes resolu- 
tion of ST segment elevation and chest pain. Although CK 
MM isoform analysis (38). computerized ST segment trend 
monitoring (39)  and signal-averaged ECG (40)  hold promise 
for more accurate noninvasive detection of reperfusion, their 
utJity in this regard is unsettled, and they are not currently 
available for routine clinical use. 
Arrhythmias. All of the arrhythmias that were observed 
in the prethrombolytic era are also seen after thrombolytic 
therapy. In fact. many studies (27-29)  have now documented 
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that the frequency of arrhythmias does not differ substan- 
tially between patients with and without reperfusion. Thus. 
all of the measures to detect, prevent and treat arrhythmias 
devised in the pre-thrombolytic era must also be used in 
pztients treated with a thrombolytic agent. During the acute 
phase of infarction, patients should be monitored continu- 
ously. Accelerated idioventricular rhythm, a particularly 
common arrhythmia in the acute phase. should be easily 
identifled by hospital staff as a wide complex arrhythmia that 
does not require treatment, except in specific limited circum- 
stances (41). The debate about the efficacy of prophylactic 
antiarrhythmic therapy in conservatively treated patients 
with infarction remains unresolved, and no controlled trials 
have specifically evaluated this issue in patiems receiving 
thrombolytic therapy. Such treatment has continued to be 
routine in our center despite the lack of definitive evidence 
for therapeutic benefit. 
Hypotension. Hemodynamic disturbances are also frs- 
quent in the early phases of acute myocardial infarction, 
even in patients who appear to be hemodynamically stable 
when treatment is initiated. It is now recognized (42) that the 
majority of patients treated with intravenous streptokinase 
will exhibit an average decrease in systolic blood pressure of 
30 mm Hg or more during the infusion. Although r&PA does 
not cause this sort of hypotensive response, 57 (8%) of 708 
consecutive TAM1 patients without cardiogenic shock on 
initiation of r&PA therapy developed sustained hypotension 
(systolic blood pressure 190 mm Hg) in the first several 
hours of treatment despite careful clinical documentation of 
adequate intravascular volume status. Hypotension oc- 
curred suddenly and unpredictably in some patients and 
progressively in others. Patients treated with thrombolytic 
therapy may, of course, develop hypotension from mechan- 
ical complications of infarction, although the incidence of 
these complications may be reduced relative to that in 
conservatively treated patients. Patients with hypotension 
unresponsive to appropriate volume resuscitation should be 
treated with intravenous pressors and should undergo 
prompt pulmonary artery catheterization and, if indicated, a 
two-dimensional Doppler echocardiographic study to look 
for evidence of ventricular septal, free wall or papillary 
muscle rupture. 
Recurrent acute isehemia. This is the “Achilles heel” of 
thrombolytic therapy. Most patients are left with a high 
grade residual stenosis in the infarct vessel and a propensity 
for reocclusion. Observed reocclusion rates have varied 
from 8 to 35%, depending on the thrombolytic regimen 
(agent, dose, duration), other interventions and the com- 
pleteness ofangiographic follow-up (21). In the TAM1 stud- 
ies, predischarge angiographic documentation of infarct ves- 
sel perfusion status has been obtained in >90% of cases. 
Table 2 shows the patency rates and the need for further 
intervention because of recurrent ischemic episodes when 
the patients from the first three TAM1 trials are combined. 
Table 2. Markers of Recurrent Ixhemla in the TAMI-I to 3 Tnalq 
In-ho\p,tal der,h 7 
R~OCClUWn 13 
Emergency CARG’ 5 
Urgent ChBG+ 5 
Emergency F’KAt 1 
‘Bypw surgery during acu!e phax of mfarctmn twtbm I2 h): :bypaqs 
wrgery before 1 days; icoronary angmplasty before 1 days. C A B G  = 
cormdry artery bypass graft wrgery: F’KA = coronary .~ngmplasty 
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thromholytic and anticoagulant therapy and immediate per- 
formance of a computed tomographic brain scan. The major 
factors associated with an increased risk of bleeding in the 
TAMI- trial (46) included lighter body weight. female 
gender, older age and history of hypertension. The most 
important predtctor of the amount oibieeding, however, was 
the performance of invasive procedures (acute angioplasty, 
intraaortic balloon pumping or surgery). The only hemato- 
logic measurements significantly associated with bleeding 
were the nadir fibrinogen and plasminogen activator inhibi- 
tor levels, but these associations were weak. The Throm- 
bolysis in Myocardial Infarction (T!MI) trial (45) found a 
significant association between plasma levels of tihrin(ogen) 
degradation ;Iroducts and the risk of bleeding, but this 
relation was also weak. Thus, the clinical utility of monitor- 
ing hematologic variables to predict the risk of bleeding after 
administration of thrombolytic agents remains unsettled. 
Cwrcnr/y, we nwaswe hen~o~~ohinlher?larocrit, p!a!elet 
CONIII, profhrombin rime and partial fhromhoplasfin time at 
baseline (before treatment) and every 6 to 8 h thereafter for 
the duration of the patient’s stay in the cardiac care unit. 
Blood is drawn in pediatric-size tubes to minimize the total 
volume removed. Bleeding without an obvious site may 
present as a decreasing systolic blood pressure with or 
without a sudden decrease in hematocrit. The partial throm- 
boplastin !ime measurement provides a rough guide to the 
adequacy of heparinization, hut has well recognized limila- 
tions. Our approach is to administer a heparin infusion 
according to the patient’s weight (15 U/kg per h starting at 
the end of the thrombolytic drug infusion) and use the partial 
thromboplastin value only to screen for gross over- or 
under-heparinization. 
Transfer to an Interventional Facility 
Regioncrlized Acute lnterventioncll Thetxpy 
Among the solutions proposed to remedy the major 
limitations of thrombolytic therapy (Table I). one of the 
more controversiai is the estabfishmrnt of a network of 
regional acute interventional catheterization centers across 
the country that are prepared to perform emergency diag- 
nostic and therapeutic procedures on patients with acute 
myocardial infarctioc. The components of regionalized acute 
interventional therapy as currently applied in our center are 
shown in Table 3. The initial component still requires the 
community physician to make a rapid diagnosis and initiate 
thrombolytic therapy promptly. After this, however, the 
patient is transferred emergently to Duke University Medi- 
cal Center, the mode of transport being determined by the 
distance, weather conditions and other related factors. The 
feasibiliiy and rakip of such emergency transport have been 
demonstrated at several centers, including our own (36,48). 
On arrival, the patient is taken directly to the interventional 
cardiac catheterization laboratory for emergency diagnostic 
Table 3. Component? of Regionalized Acute 
Intervention31 Therapy pp----- 
1. Therapy iniaated as soon as possible by community physician 
2. Rapid transpon to x~te interventional center 
Mobile inttnsive cilre unit 
H~licnntrr (rlW mdes 1240 km!) . . , 
Fixed wing (>I50 mile5 I240 kmll 
3. Emergency cardiac cnthetcrization 
4. Triage to proper therapy 
Acute conmar) anpioplasly 
Deferred coronary angioplasly 
Acute bypass surgery 
Deferred bypas5 surgery 
Coronary care umtlmcdical therapy 
-  
catheterization. Deoendinr! on the findings at angiography 
(Fig. 1). the patient-may &en undergo an-emergency revas- 
cularization procedure or be sent to the cardiac care unit for 
monitorine and. cossibly, a delayed revascularization pro- 
cedure. If the dklayed -option is selected and the patient 
the laboratory (or to the operating room if surgery is prefer- 
able) for an emergency procedure. 
Other possible approaches include keeping the patient at 
the community hospital after administration of thrombo!ytic 
therapy and reserving emergency transport to the interven- 
tional center for patients with recurrent ischemia. Although 
much information has now been collected about the feasibil- 
itv and ootential utilitv of regionalized interventional ther- 
apy. 
role 
patients with a&e myocardial infarction. We will first 
consider the arguments favoring a more conservative ap- 
proach (Table 4). We will then examine the arguments 
supporting the value of immediate angiography (Table 5). 
Argwnents for (I Conservative Strategy 
To stm~ort a recommendation that all patients with acute . . 
myocardial infarction be moved to a regional acute interven- 
Figure I. Revascularizatioa strategies after emergency angioplasty 
in myocardial infarction. CABG = coronary artery bypass graft 
surgery; RCA = coronary angioplasty: VD = vessel disease. 
*Includes patient. with TIM1 grade 2 flow and continued ischemic 
signs and symptoms. 
tional center promptly after the imtulimn of thromholyuc 
therapy, we need convincing evidence lhal the greater 
concentration of technologic resource\ in \uch a center 
would !ead to a better clinical outcome for the patient at an 
acceptable cost. Such information currently does not exist 
and, in fact, substantial evidence has accumulated that. at 
least in certain situations, a noninvasive strategy leads to an 
equivalent or even more desirable clinical recult f 17.49.50). 
There are now several major reasons why a conservative 
strategy involving rapid administration of thrombolytic ther- 
apy to appropriate candidates with hospitalization in the 
community hospital (as long as their condition remains 
uncomplicated) may be preferable (Table 4). 
Role of immediate coronary angloplasty. The wisdom of 
immediate intervention in ?he catheterization laboratory 
has been called into question by three recent randomized 
clinical trials (17.49.50) (Table 6). Each trial included >350 
patients, although only I97 were actually randomized in the 
TAM&I trial. In the TAMI-I trial, high dose r&PA (150 mg) 
was used in all patients, whereas the TIMI-IIA trial switched 
from high dose rt-PA to a fixed dose of 100 mg one-third of 
the way through the trial (50). The European Cooperative 
Study Group (49)  used a IO0 mg dose of rt-PA through%~ 
their trial. The TAMI-I trial (17)  randomized patients only 
after documenting arterial patency and anatomy suitable for 
coronary angioplasty with immediate angiography. while 
both the TIMI and European trials randomized patients 
before the administration of thrombolytic therapy. Thus, the 
latter two trials included emergency catheterization as part 
of the interventional strategies they were testing, whereas 
the TAM1 trial did not. A major difference among the trials 
was the selection of patients for angioplasty. The TAMI-I 
and the TIMI-11A trials tested the vaiue of coronary an& 
plasty in patients believed to have coronary anatomy suit- 
able for angioplasty, whereas the European study tested the 
value of emergency angioplasty in virtually all patients with 
TabYe 5. Arguments Favoring an Aggressive Strategy 
-_ 
1.1 Only reliable way lo idenbfy reperlusw~ fadure for tnage 10 reue 
,  revawlarizatian 
Z”.\llorrs early identificabon of pabentc wth high rusk cwonary anatomy 
lesicns (e.g.. left main coronary awry dwase) heedmg urgent WWY 
3 Potendal benefits of emergency coronery dngloplerty m cdrdmgemc 
shock 
4. F.arly mobilizatton and dncharge of low n\k pabent\ 
-  
94 
lmd 
a \Igmficant Infarct vessel stenosis randomized lo the aggres- 
Slve \trateav (Table 6)  
T/W TrlifI-/ s&y (17)  demonstrated that, after success- 
ful reperfuslon with intravenous high dose &PA (IjO mg 
over 6 to 8 h). emergency angiopldsty did not lead to better 
global or  regional left ventricular function compared with 
a strategy of deferred revascularization. In Interpreting 
ttus study, it is important to keep in mind ISat a critical 
component of the deferred revasculariration strategy 
was the ability to perform emergency revascularization if 
recurrent &hernia occurred. Most secondary end points did 
not differ between the two treatmeut qtrdtegies, but the 
immediate angioplasty group had a higher rate of emergency 
bypass surgery and a slightly higher in-hospital mortality 
rate (not statistically significant) compared with the deferred 
group. 
T/W TIMMA rrictl, in a preliminary report ISO). found 
randomized to immediate catheter- 
(performed if technically feasible) 
had a higher rate if emergency surgery and reinfarction and 
no imorovement in left ventricular function compared with 
patie& undergoing deferred catheterization (and angio- 
plasty as indicated) at I8 to 48 h after symptom onset. 
i/w Empmn Cooperdve Sf~dy G’rmp (49)  randomized 
patients to receive either immediate catheterization and 
angioplasty or  conservative therapy after administrafion of 
rt-PA. Aggressively treated patients had a higher (though 
statistically nonsignificant) mortality rate, a higher rate of 
recurrent ischemiain the first 24 h after admission and higher 
prevalence of hypotension. ventricular fibrillation and bleed- 
ine. 
-Conservative versus aggressive approach. The results 
from these trials demonstrate that a conservative strategy 
after rt-PA administration is as effective as a strategy oT 
immediate catheterization and angioplasty where possible. 
Although it if tempting to conclude that these studies have 
demonstrated conclusively that emergency catheterization is 
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not useful, seveml caveats are in order. First, all three trials 
used rt-PA alone as the thrombolytic agent. Nonrandomized 
comparisons (16,51,52) suggest that immediate angioplasty 
results (particularly reocclusion rates) may be worse with 
r&PA alone compared with other thrombolytic agents or 
combinations of agents. Second, all three trials closely 
coupled the immediate angiogiam with the angioplasty. The 
angiogram was viewed primarily as a prelude to angioplasty, 
particularly in the European trial, rather than as a diagnostic 
test providing information for triage of the patient to the 
most appropriate revascularization strategy. Perhaps the 
clearest lesson from these trials is that a policy of deferred 
angioplasty is preferable in patients with adequate perfusion 
after thrombolysis. 
Costs of aggressive versus conservative management. One 
of the most compelling arguments for a conservative man- 
agement strategy after administration of thrombolytic ther- 
apy is the high cost of the acute interventional strategy. 
Roughly I million people in the United States present to 
medical facilities each year with an acute myocardial infarc- 
tion. Because the majority of these present to hospitals 
without acute interventional facilities, an aggressive treat- 
ment strategy would require these patients to be moved (by 
a mobile intensive care unit, helicopter or jet) to an inter- 
ventional center (Table 3). Maintaining such a system of 
emergency transportation for patients with acute myocardial 
infarction is costly in dollars and health care resources used. 
Transport vehicles must have full intensive care unit capa- 
bilities and are expensive to outfit and maintain. Highly 
skilled (and highly paid) intensive rare nurses and pilots are 
required to statf these transport vehicles. Communication 
systems must be purchased and maintained, and a system of 
dispatchers, mechanics and other support personnel must be 
hued. Overall., a sophisticated emergency transport system 
represents a considerable expenditure that, in economic 
terms at least, takes money and resources away from other 
health care programs. 
Similarly, a large cost is incurred in establishing and 
maintaining a 24 h an&graphic facilify. Technicians and 
nurses usually require overtime pay to be on call, and these 
personnel (as well as angiographers) become less efficient 
during the day after being on call. Scheduled elective angio- 
plasty procedures may have to be deferred because of the 
priority of the “emergency” case, leading to frustration of 
both patients and physicians and, potentially, a prolonged 
hospital stay for patients undergoing an elective procedure. 
Other important costs associated with an aggressive strategy 
include the cost of an emergency cardiac catheteriz Ation 
and, when necessary, emergency coronary angioplasty or 
bypass surgery. 
CompIIItkms. In the setting of thrombolytic therapy, 
any invasive procedure such as cardiac catheterization is 
associated with a significantly increased incidence of bleed- 
ing complications. The only bleeding complication that com- 
monly results in major disability or death is intracranial 
hemorrhage, which is presumably unrelated to the perfor- 
mance of cardiac catheterization or other procedures. Other 
major bleeding, however, may necessitate transfusion ther- 
apy, thereby exposing the patient to the small but finite risk 
of transfusion reactions or future disease (principaliy hepa- 
titis). 
Finally, it remains uncertain whether prompt aggressive 
revascularization of patients developing recurrent isehemia 
(one argument for moving patients early to an interventional 
center) is associated with a more favorable outcome than is 
an aggressive medical regimen (possibly including repeat 
administration thrombolytic therapy). The optimal manage- 
ment of recurrent ischemia remains to be defined. 
Arguments in Favor of Imm&iate Angiography 
Although three randomized clinical trials have demon- 
strated that immediate arrgioplasty is not necessary, at least 
when successful thrambolysis has been achieved, there are 
several other arguments favoring early angiography (Table 
5). Perhaps the most compelling is that emergency cathetcr- 
izatiot is the only currently reliable way to identify patients 
who have failed thrombolytic therapy and who will, there- 
fore, not achieve the therapeutic benefits of early reperfu- 
sion without further intervention (28,29,37). Studies to date 
have identified four major conseqtiences associated with 
failure of reperfusion after the administration of thromboly- 
tic therapy: diminished long-term survival, worse left ven- 
tricular function, more congestive heart failure and more 
arrhythmias (Table 7). 
Long-term survivak The Western Washington trial (6) of 
intracoronary streptokinase initially reported a dramatic 
difference in the I year survival rate when patients with 
complete reperfusion of the infarct-related artery were com- 
pared with patients with incomplete or no reperfusion. Since 
that time, both the TAMI-I and TIM1 phase I trials (53.54) 
have reported follow-up data showing a substantial differ- 
ence in mortality rates between patients with early pharma- 
cologic reperfusion and patients who did not have reperfu- 
sion. In the Duke experience (35) with intravenous 
thrombolysis and angioplasty, the in-hospital mortality rate 
was 15% in patients with initial failure of reperfusion com- 
pared with 5% in those with pharmacologic reperfusion. In 
both the Duke experience and the TAMI-I trid, the survival 
rates of hospital survivors with and without early reperfu- 
sion were very high, with I year rates in both groups of 
approximately 98%. These high survival rates after dis- 
charge were seen even in very high risk subgroups, such as 
patients presenting in cardiogenic shock (35). In contrast, in 
both the TIM1 phase I trial and the Western Washington 
trial, patients without initial pharmacologic reperfusion con- 
tinued to have a high mortality rate after hospital discharge. 
The major difference in the therapeutic algorithm in these 
Table 1. Short- and Long-Term Motr.d~ty R.~te\ m bl,~~ot 
Thrombolysis Trial\ 
TIMI- ;n=31h, In-ho\p,l.,l 
TIM1 11-111 4 v: 
TIM1 O-I 
TAM14 (n= 3%) 
TIMI 11-111 
TIM1 0.1 
Duke SWPTCA In=342 
TIM1 11-111 
TIM1 O-I 
I4 vi 
IYe,lr 
h  Y’r 
IO J’r 
IYe.rr 
7v 
I?? 
ISAM (n=l.741) 3Wsek\ lYerr 
Stteprokmase group 6 3Y I!‘; 
Placebo group 7 I’i I vi 
GISSI (n=11,711l In-howal Iye.lT 
Stteptokinae group Ii) 7v 17 ?‘i 
Control group na IW 
AIMS trial In= I .004) ~ IYe,lr 
.ZPSAC group h J’i 1”  xv 
Placebo group I? IV 19 .I? 
ISIS-2 (n=l7.189) SWeek\ lYe.lr 
Srteptokmase group x.95; ,$‘I: 
Placebo group 11.7% IX’: 
AIMS = APSAC lntetventmn Mondhty Sludy. APSAC = amwyl~wd 
plasminogen stteptokinaw aclv~&ot complex: GIFSI = Gtuppo h&no pet II) 
Studio della Stteptochinasi nell’lnfatlo M~ocatd~o. ISIS-? = Second Inset- 
national Study of Infarct Sutvwal. ISAM = lnltdvenuu~ Slteptokmdx an 
Acute Mywatdial Infarction sludv: PTCA = cotandty dngmpla\ly. SK = 
stteptokinase: TAMI = Thtomboly515 and Angmplarty m Myocatdtal Infxc- 
don study: TIM1 = Thtomboly~~s m Myocatdul lnbtcl~on Judy. WW IC SK 
= Western Washington Inlrxoronary Sttepiokmdw Judy 
different studies was that in the Duke and TAMI protocols. 
substantial efforts were made to achieve “rescue” revascu- 
larization with angioplasty or  surgery in the majority of 
patients who had unsuccessful thrombolytic therapy. 
whereas attempts at mechanical revascularization were not 
made in the Western Washington study and were variable in 
the TIM1 trial. 
In the /urge rundomized rrilds of fhromholysis rhtrr hcrw 
reported long-term follow-up cfrrrcr fTuh/e 7), the mortality 
rate between hospital discharge and I year averages approx- 
imately 6% and is virtually the same in the treatment and 
control groups despite a presumably higher early coronary 
reperfusior, rate in the treatment groups. Thus, although 
successful reperfusion with thrombolytic therapy is associ- 
ated with a significant reduction in short-term mortality. 
additional reductions in long-term mortality have been srrn 
only in those studies that employed an aggressive approach 
to early revascularization. 
hrt Witricular function and congestire failure. Multiple 
t:mdomr/cd ttralc have now confirmed the other major 
~cquclac t)f thrombolysis failure. Patients given placebo or  
con\ctvi,tttvc therapy in randomized trtals have had con+ 
len!ly poorpt left ventricular function than that of patients 
glw’n lhtomhol+c therapy 17-10.55). Failure to wlvage 
myocatdmm h,is been as\ociatetf with a higher prevalence of 
\ymptomatrc csmgestive heart failure in the control groups in 
the<e ttral\ (8). In an analycis of factors associated with 
tmprovement at global and regional left ventricular function 
m the TAMI-I trial (56). the early establishment of pharma- 
cologtc reperfusion and the maintenance of perfusion IO the 
mfatct area for the dcration of the hospitalization were the 
mo\t ctmcal clinical factors. 
Mo\t mve\tigators agree that the salvage of ischemic 
myocardtum by early reperfusion is a major factor in 
Improving long-term prognosis after myocardial infarction. 
Additional evidence has been developed, however. that 
\u\tamed infarct vessel patency may confer significant 
progno\trc benefits independent of measurable early myo- 
catdial \alvage. Presumably. sustained perfusion of the 
infarct territory improves the process of infarct “t,ealing” 
and prevent\ or  reduces infarct expansion. Most t vidence 
for tht\ phenomenon has been derived from comparison of 
animal mode’s in which reperfusion was established after the 
time wmdow for myocardial salvage with other animal hearts 
where the coronary artery was left chronically occluded. 
Pathologic analysis (57)  of the myocardium has demon- 
strated le\\ expansion of the infarcted area and less aneu- 
rysm formatton in the animals with repcrfttsion. A recent 
study (58)  from the University of Virginia found that reper-  
fuGon with streptokinare was associated with a reduced 
incidence of Infarct expansion as assessed by echocardiog- 
raphy. even though some patients had no im;liovement in 
left ventricular ejection fraction. 
Ventricular arrhythmias. Two small studies (59.60) have 
compared electrophysiologic lest results in patients with and 
without reperfusion after thrombolytic therapy. In a sub- 
study of the Dutch Interuniversity randomized trial of slrep 
tokinahe (59). I7 patients with reperfusion had a much lower 
prevalence of inducible ventricular tachycardia than that of 
I9 patient9 without reperfusion. More recently. Sager et al. 
(60)  reported that 7 (88%) of 8 patients with anterior wall 
infarction complicated by development of a left ventricular 
aneurysm who did not receive thrombolytic therapy had 
inducible ventricular tachycardia compared with only I (8%) 
of I2 patients with anterior infarction and a left ventricular 
anemysm who did receive thrombolytic therapy. During 
follow-up study (average I I months), no patient treated with 
thrombolytic therapy died or  had an arrhythmic event, 
whereas hatf of the patients who did not receive such 
therapy either died suddenly or  developed sustained ventric- 
ular tachycardia (60). We and others (40)  have recently 
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Figure 2. Protocol for the Thrombolysis and Angioplasty in Myo- 
cardial Infarction-5 trial of six different coronary reperfusion s1ra1- 
eeies in acute mvocardial infarction. CATH = cardiac catheteriza- 
t&n; &PA recombinani tissue plasminogen activator: UK = 
urokinase. 
senting in cardiogenic shock. Most randomized trials of 
acute interventional therapy have either excluded patients in 
shock or enrolled a very low proportion of such patients. 
Some preliminary observational data (63) have suggested 
that patients in shock have more improvement in left ven- 
tricular function when thrombolysis is coupled with a 
prompt reduction of the residual infarct vessel stenosis 
compared with thrombolysis alone. 
Reduced hospital stay. Finally, emergency cardiac cath- 
eterization, by promptly identifying high and low risk ana- 
tomic subsets and setting the stage for early revasculariza- 
tion of selected subsets, may make it possible for some 
patients to be more aggressively mobilized and discharged 
from the hospital in 3 or 4 days, rather than the current 7 to 
10 days. Data from Top01 et al. (64), including a randomized 
controlled trial. support the feasibility and safety of very 
early discharge in selected patients. A strategy of early 
identification of patients with a critical residual stenosis after 
thrombolysis, coupled with early (0 to 48 h) angioplasty, 
rapid in-hospital mobilization and early discharge may im- 
prove functional and psychological recovery and increase 
return to work rates. 
TAM14 Trial 
To evaluate the uiility ot a regionalized acute interven- 
tional approach to treatment of acute myocardial infarction, 
the TAM1 Wudy Group is currently conducting a trial 
comparing six different reperfusion strategies (Fig. 2). Pa- 
tients are being randomized to receive one of three throm- 
bolytic therapy regimens @t-PA alone. rt-PA and urokinase 
in combination and urokinase alone) and one of two triage 
strategies. One triage strategy will involve immediate trans- 
fer of the patient to an interventional center, immediate 
catheterization and assignment to a revascularization strat- 
egy based on the clinical and angiographic findings. The 
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other strategy will involve keeping the patlent at the com- 
munity hospital for a week after admuustration of throm- 
bolytic therapy with transfer to an interventional center only 
for objectively documented recurrent ixhemla or  unex- 
plained pump dysfunction. 
Thiz !r!‘d wi!! differfrnm thr previmrc rrids edrrtrtinp the 
,;mp (?f <‘““in”yd... 0.-e .-I,*., in i&C ~iiiportcinf respects: FeYed 
thrombolytic regimens will be tested. and anmography wdl 
be uncoupled from angioplasty so that immediate angle- 
plasty will be performed only on patients with fadure of 
thrombolytic therapy or  with ongoing lschemia in the pre+ 
ence of a critical infarct vessel lesion. End points of the trial 
include left ventricular function assessed at 7 to IO days and 
6 weeks, recurrent ischemic event rates for the first 6 months 
of follow-up, predischarge infarct artery patency rates. 
bleeding episodes and medical costs over :he 1st year after 
enrollment. Enrollment into the trial is scheduled to be 
completed in early 1989. 
Summary 
Ample evidence is now available to indicate that throm- 
bolytic therapy should be initiated in patients with ac,lte 
myocardial infarction as rapidly as posible under the super- 
vision of a physician. Paramedic or  nurse-imtiated pre-  
hospital therapy is currently under investigation. but this 
approach cannot be recommended until more data are 
available. Every community medical facility receiving pa-  
tients with acute myocardial infarction should have a care- 
fully planned thrombolytic therapy protocol for patient se- 
lection, administration of drug and patiem monitoring after 
therapy is instituted. The role of early catheterization and 
aggressive revascularization in patients who have unsuc- 
cessful thrombolysis is the subject of the ongoing TAM-5 
trial. 
Recent clinical trials have provided evidence (both direct 
and indirect) that an open infarct-related vessel confers 
important prognostic benefits, even when myocardial sal- 
vage is unmeasurable. Newer thrombolytic agents, combi- 
nations of agents and adjunctive therapies (such as agents to 
reduce reperfusion injury or  to reduce the reocclusion rate 
after successful thrombolysis) may. in a few years, provide 
all the benefits of aggressive therapy with a lower risk and 
cost. On the other hand, coronary stems, atherectomy and 
laser techniques are likely to improve our  ability to establish 
and sustain coronary patency, perhaps dramatically. Effec- 
tive early intervention may minimize hospitalization needs 
and promote effective rehabilitation and early return to 
work. With each new pharmacologic and technologic ad-  
vance, the results of previous clinical trials and cxrent 
clinical practice will need to be reassessed. 
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